# Analgesic Effectiveness of Three Different Doses of a New Formulation of Lamaline in a Model of Painful Knee (Gonarthrosis)

> **NCT00264225** · PHASE3 · COMPLETED · sponsor: **Solvay Pharmaceuticals**

## Conditions studied

- Knee Osteoarthritis

## Interventions

- **DRUG:** Lamaline® , 3 different doses, Dafalgan codeine

## Key facts

- **NCT ID:** NCT00264225
- **Lead sponsor:** Solvay Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2008-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00264225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00264225, "Analgesic Effectiveness of Three Different Doses of a New Formulation of Lamaline in a Model of Painful Knee (Gonarthrosis)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00264225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*